XML 43 R30.htm IDEA: XBRL DOCUMENT
v3.19.1

Supplemental data | 3 Months Ended
--- | ---
Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Supplemental data | Supplemental data The following information is presented as supplemental data as required by the indentures governing the Company’s senior notes. Condensed Consolidating Statements of Income
|  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
For the three months ended March 31, 2019 |  |  |  |
Patient service operating revenues |  | $ | 2,635,152 |  |  | $ | — |  |  | $ | — |  |  | $ | 2,635,152 |
Provision for uncollectible accounts |  | (5,463 | ) |  | — |  |  | — |  |  | (5,463 | )
Net patient service operating revenues |  | 2,629,689 |  |  | — |  |  | — |  |  | 2,629,689 |
Other revenues |  | 113,423 |  |  | — |  |  | — |  |  | 113,423 |
Total net operating revenues |  | 2,743,112 |  |  | — |  |  | — |  |  | 2,743,112 |
Operating expenses |  | 2,402,605 |  |  | — |  |  | — |  |  | 2,402,605 |
Operating income |  | 340,507 |  |  | — |  |  | — |  |  | 340,507 |
Debt expense |  | (131,519 | ) |  | — |  |  | — |  |  | (131,519 | )
Other income |  | 6,940 |  |  | — |  |  | — |  |  | 6,940 |
Income tax expense |  | 56,746 |  |  | — |  |  | — |  |  | 56,746 |
Net income from continuing operations |  | 159,182 |  |  | — |  |  | — |  |  | 159,182 |
Net income from discontinued operations, net of tax |  | 30,305 |  |  | 9,237 |  |  | 463 |  |  | 20,605 |
Net income |  | 189,487 |  |  | 9,237 |  |  | 463 |  |  | 179,787 |
Less: Net income attributable to noncontrolling interests |  | (40,198 | ) |  | (1,255 | ) |  | — |  |  | (38,943 | )
Net income attributable to DaVita Inc. |  | $ | 149,289 |  |  | $ | 7,982 |  |  | $ | 463 |  |  | $ | 140,844 |
(1) | After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Statements of Comprehensive Income
|  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
For the three months ended March 31, 2019 |  |  |  |
Net income |  | $ | 189,487 |  |  | $ | 9,237 |  |  | $ | 463 |  |  | $ | 179,787 |
Other comprehensive loss |  | (12,627 | ) |  | — |  |  | — |  |  | (12,627 | )
Total comprehensive income |  | 176,860 |  |  | 9,237 |  |  | 463 |  |  | 167,160 |
Less: Comprehensive income attributable to the noncontrolling interests |  | (40,198 | ) |  | (1,255 | ) |  | — |  |  | (38,943 | )
Comprehensive income attributable to DaVita Inc. |  | $ | 136,662 |  |  | $ | 7,982 |  |  | $ | 463 |  |  | $ | 128,217 |
(1) | After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Balance Sheets
|  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
As of March 31, 2019 |  |  |  |
Cash and cash equivalents |  | $ | 459,242 |  |  | $ | — |  |  | $ | — |  |  | $ | 459,242 |
Restricted cash and equivalents |  | 102,192 |  |  | — |  |  | — |  |  | 102,192 |
Accounts receivable, net |  | 1,953,422 |  |  | — |  |  | — |  |  | 1,953,422 |
Other current assets |  | 705,272 |  |  | — |  |  | — |  |  | 705,272 |
Current assets held for sale, net |  | 6,004,948 |  |  | 629,422 |  |  | 3,288 |  |  | 5,372,238 |
Total current assets |  | 9,225,076 |  |  | 629,422 |  |  | 3,288 |  |  | 8,592,366 |
Property and equipment, net |  | 3,392,266 |  |  | — |  |  | — |  |  | 3,392,266 |
Operating lease right-of-use assets |  | 2,736,536 |  |  | — |  |  | — |  |  | 2,736,536 |
Amortizable intangibles, net |  | 118,324 |  |  | — |  |  | — |  |  | 118,324 |
Other long-term assets |  | 334,374 |  |  | — |  |  | — |  |  | 334,374 |
Goodwill |  | 6,799,368 |  |  | — |  |  | — |  |  | 6,799,368 |
Total assets |  | $ | 22,605,944 |  |  | $ | 629,422 |  |  | $ | 3,288 |  |  | $ | 21,973,234 |
Current liabilities |  | $ | 6,477,567 |  |  | $ | — |  |  | $ | — |  |  | $ | 6,477,567 |
Current liabilities held for sale |  | 1,753,310 |  |  | 412,368 |  |  | — |  |  | 1,340,942 |
Payables to parent |  | — |  |  | 72,539 |  |  | 3,288 |  |  | (75,827 | )
Long-term operating leases liabilities |  | 2,625,776 |  |  | — |  |  | — |  |  | 2,625,776 |
Long-term debt and other long-term liabilities |  | 6,519,574 |  |  | — |  |  | — |  |  | 6,519,574 |
Noncontrolling interests subject to put provisions |  | 1,143,044 |  |  | — |  |  | — |  |  | 1,143,044 |
Total DaVita Inc. shareholders’ equity |  | 3,875,354 |  |  | 144,515 |  |  | — |  |  | 3,730,839 |
Noncontrolling interests not subject to put provisions |  | 211,319 |  |  | — |  |  | — |  |  | 211,319 |
Shareholders’ equity |  | 4,086,673 |  |  | 144,515 |  |  | — |  |  | 3,942,158 |
Total liabilities and shareholder’s equity |  | $ | 22,605,944 |  |  | $ | 629,422 |  |  | $ | 3,288 |  |  | $ | 21,973,234 |
(1) | After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Statements of Cash Flows
|  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
For the three months ended March 31, 2019 |  |  |  |
Cash flows from operating activities: |  |  |  |  |  |  |  |
Net income |  | $ | 189,487 |  |  | $ | 9,237 |  |  | $ | 463 |  |  | $ | 179,787 |
Changes in operating and intercompany assets and liabilities and non-cash items included in net income |  | (48,183 | ) |  | 9,696 |  |  | (463 | ) |  | (57,416 | )
Net cash provided by operating activities |  | 141,304 |  |  | 18,933 |  |  | — |  |  | 122,371 |
Cash flows from investing activities: |  |  |  |  |  |  |  |  |  |  |  |
Additions of property and equipment |  | (198,878 | ) |  | (229 | ) |  | — |  |  | (198,649 | )
Acquisitions |  | (11,274 | ) |  | — |  |  | — |  |  | (11,274 | )
Proceeds from asset and business sales |  | 13,903 |  |  | — |  |  | — |  |  | 13,903 |
Investments and other items |  | (4,109 | ) |  | (1,355 | ) |  | — |  |  | (2,754 | )
Net cash used in investing activities |  | (200,358 | ) |  | (1,584 | ) |  | — |  |  | (198,774 | )
Cash flows from financing activities: |  |  |  |  |  |  |  |  |  |  |  |
Long-term debt |  | 357,197 |  |  | — |  |  | — |  |  | 357,197 |
Intercompany |  | — |  |  | 28,965 |  |  | — |  |  | (28,965 | )
Other items |  | (32,246 | ) |  | — |  |  | — |  |  | (32,246 | )
Net cash (used in) provided by financing activities |  | 324,951 |  |  | 28,965 |  |  | — |  |  | 295,986 |
Effect of exchange rate changes on cash, cash equivalents and restricted cash |  | (921 | ) |  | — |  |  | — |  |  | (921 | )
Net increase in cash, cash equivalents and restricted cash |  | 264,976 |  |  | 46,314 |  |  | — |  |  | 218,662 |
Less: Net increase in cash, cash equivalents and restricted cash from discontinued operations |  | 118,962 |  |  | 46,314 |  |  | — |  |  | 72,648 |
Net increase in cash, cash equivalents and restricted cash from continuing operations |  | 146,014 |  |  | — |  |  | — |  |  | 146,014 |
Cash, cash equivalents and restricted cash of continuing operations at beginning of the year |  | 415,420 |  |  | — |  |  | — |  |  | 415,420 |
Cash, cash equivalents and restricted cash of continuing operations at end of the period |  | $ | 561,434 |  |  | $ | — |  |  | $ | — |  |  | $ | 561,434 |
(1) After elimination of the unrestricted subsidiaries and the physician groups.

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration